Apoquel vs Atopica for Dogs: Choosing the Right Allergy Treatment

By Emiel Maddens  ·  Reviewed in consultation with licensed veterinary professionals  ·  Updated June 2026  ·  10 min read

Photo by Anya Prygunova on Unsplash

When a dog suffers from chronic atopic dermatitis, veterinarians most commonly reach for one of two oral medications: Apoquel (oclacitinib) or Atopica (cyclosporine). Both drugs have transformed how veterinary medicine manages allergic skin disease, offering alternatives to long-term corticosteroid use. However, these medications work through entirely different mechanisms, carry different risk profiles, and are suited to different clinical scenarios. Understanding these distinctions is essential for every dog owner navigating treatment decisions with their veterinarian.

Apoquel arrived on the veterinary market in 2013 and quickly became one of the fastest-selling animal health products in history. Its appeal lies in rapid onset, with most dogs experiencing significant itch relief within the first day of treatment. Atopica, which contains cyclosporine, has been available since 2003 and takes a fundamentally different approach. Rather than blocking specific itch pathways, cyclosporine broadly modulates the immune system to reduce the inflammatory cascade that drives allergic symptoms. Each medication has earned its place in veterinary dermatology for good reasons.

Choosing between these two treatments is rarely straightforward. Factors including your dog's specific diagnosis, age, concurrent health conditions, your household budget, and your tolerance for potential side effects all play a role. This comprehensive guide walks through everything you need to know about both medications, from their molecular mechanisms to real-world cost comparisons, so you can have an informed conversation with your veterinarian about which option makes the most sense for your dog.

How Apoquel Works: The JAK Inhibitor Approach

Apoquel belongs to a class of drugs known as Janus kinase (JAK) inhibitors. JAK enzymes are intracellular signaling molecules that transmit signals from cytokines, the chemical messengers involved in inflammation and immune responses. When allergens trigger an immune response in a dog's skin, cytokines like interleukin-31 (IL-31) bind to receptors on nerve cells and immune cells, activating JAK enzymes that carry the itch and inflammation signals forward. Apoquel selectively inhibits JAK1 and JAK3, effectively blocking these signaling pathways before they produce the sensation of itch or the inflammatory response.

Rapid Onset and Duration of Action

One of Apoquel's most significant clinical advantages is its speed. Clinical studies have demonstrated measurable itch reduction within 4 hours of the first dose, with substantial relief typically achieved within 24 hours. This rapid response makes it particularly valuable for dogs in acute distress, where immediate comfort is a priority. The drug is administered twice daily for the first 14 days, then typically reduced to once daily for maintenance therapy. Each dose lasts approximately 12 to 24 hours, which means missed doses can result in a noticeable return of symptoms relatively quickly.

Selectivity and Specificity

While Apoquel is often described as a targeted therapy, it is important to understand that JAK1 and JAK3 are involved in multiple immune pathways beyond just itch signaling. JAK1 participates in signaling for interferons, IL-6, and other cytokines important for immune surveillance. This means Apoquel does not exclusively block itch; it has broader immunomodulatory effects that must be considered, particularly in dogs with concurrent infections or immune challenges. Clinical data suggests that while Apoquel is more targeted than corticosteroids, it is not as narrowly focused as some newer biologic therapies like Cytopoint.

Approved Uses and Dosing

Apoquel is FDA-approved for the control of pruritus associated with allergic dermatitis and the control of atopic dermatitis in dogs at least 12 months of age. The standard dosing is 0.4 to 0.6 mg/kg administered orally twice daily for up to 14 days, followed by 0.4 to 0.6 mg/kg once daily for maintenance. It should not be used in dogs under 12 months old because of the JAK pathway's role in normal immune system development during that critical growth period.

How Atopica Works: The Calcineurin Inhibitor Approach

Atopica contains cyclosporine, a calcineurin inhibitor originally developed for use in human organ transplant medicine. Calcineurin is an enzyme that plays a central role in activating T-lymphocytes, the white blood cells that drive much of the allergic inflammatory response. When cyclosporine binds to cyclophilin inside T-cells, the resulting complex inhibits calcineurin, preventing the transcription of interleukin-2 and other pro-inflammatory cytokines. This effectively reduces the overactive immune response responsible for allergic skin disease without completely suppressing the entire immune system.

Gradual Onset and Building Efficacy

Unlike Apoquel's rapid action, Atopica requires patience. Most dogs begin showing noticeable improvement within 2 to 4 weeks of starting treatment, but full therapeutic benefit may not be apparent for 4 to 6 weeks. This slower onset reflects cyclosporine's mechanism of action, which involves fundamentally shifting the immune system's behavior rather than simply blocking a signaling pathway. For this reason, veterinarians sometimes prescribe a short course of corticosteroids or Apoquel alongside Atopica during the initial weeks to provide immediate comfort while cyclosporine reaches therapeutic levels.

Broader Immunomodulatory Effects

Cyclosporine's effects extend beyond T-cell suppression. It also inhibits mast cell degranulation, reduces eosinophil activity, and decreases the production of various pro-inflammatory mediators. This broader immunomodulatory profile makes Atopica effective for conditions that go beyond simple allergic itch, including perianal fistulas, sebaceous adenitis, and certain forms of immune-mediated skin disease. Veterinary dermatologists sometimes prefer cyclosporine precisely because of this wider therapeutic range.

Dosing and Administration Considerations

Atopica is typically administered at 5 mg/kg once daily, ideally on an empty stomach to maximize absorption. Giving cyclosporine with food can reduce bioavailability by up to 22 percent, though some veterinarians accept this trade-off for dogs that experience gastrointestinal side effects. Once clinical improvement is achieved, many dogs can be transitioned to every-other-day or twice-weekly dosing, which significantly reduces long-term costs. This dose-reduction protocol is one of Atopica's practical advantages over Apoquel, which generally must be maintained at daily dosing to sustain efficacy.

Understanding the differences between Apoquel and Atopica helps owners and veterinarians make informed treatment choices.

Photo by Alexander Mass on Unsplash

Side Effect Profiles: What to Watch For

Both Apoquel and Atopica carry potential side effects, but their profiles differ substantially. Understanding these differences is crucial for monitoring your dog during treatment and for making an informed choice between the two medications. Neither drug is without risk, and both require regular veterinary oversight to ensure safety during long-term use.

Apoquel Side Effects

The most commonly reported side effects of Apoquel include vomiting, diarrhea, decreased appetite, and lethargy, particularly during the initial two-week loading period. More concerning is Apoquel's potential impact on immune surveillance. Because JAK1 signaling is involved in the body's defense against infections and abnormal cell growth, long-term Apoquel use has been associated with increased susceptibility to skin infections, urinary tract infections, and, in some studies, a higher incidence of certain tumors. The FDA label notes that Apoquel may increase susceptibility to infection and exacerbate neoplastic conditions. Dogs on Apoquel should receive regular veterinary check-ups, including bloodwork every 6 to 12 months to monitor for changes in white blood cell counts and liver values.

Atopica Side Effects

Gastrointestinal upset is by far the most common side effect of Atopica, affecting approximately 25 to 30 percent of dogs when treatment begins. Vomiting, diarrhea, and soft stools typically occur during the first few weeks and often resolve as the dog adjusts to the medication. Freezing the capsules before administration can help reduce nausea in many dogs. Less common side effects include gingival hyperplasia (overgrowth of the gums), excessive hair growth, and papilloma-like skin lesions. Because cyclosporine is immunosuppressive, dogs on Atopica should avoid live vaccines and should be monitored for signs of infection.

Comparing Long-Term Safety Data

Apoquel has now been on the market for over a decade, and post-market surveillance data has provided a clearer picture of its long-term safety profile. Studies published in veterinary dermatology journals have documented rare but notable cases of demodicosis, new skin masses, and opportunistic infections in dogs on long-term Apoquel therapy. Cyclosporine has an even longer track record in both human and veterinary medicine, spanning several decades. While its immunosuppressive nature warrants monitoring, the long-term safety data for cyclosporine at the doses used in veterinary dermatology is generally reassuring. Both drugs require ongoing veterinary oversight, and neither should be considered entirely without risk during extended use.

Cost Comparison: Apoquel vs Atopica

Cost is often a deciding factor for pet owners managing chronic skin disease, especially since both medications are typically prescribed for long-term or lifelong use. The financial impact varies considerably based on your dog's weight, the pharmacy you use, and whether generic alternatives are available.

Monthly Cost Breakdown

For a 30-pound dog, Apoquel typically costs between $60 and $90 per month at standard dosing. The cost scales linearly with weight, meaning a 70-pound dog may pay $120 to $180 per month. Brand-name Atopica tends to be comparable or slightly more expensive than Apoquel for smaller dogs, but generic cyclosporine (which is bioequivalent) can reduce costs by 30 to 60 percent. A 30-pound dog on generic cyclosporine might pay $40 to $70 per month, and this cost drops further if the dog can be maintained on every-other-day dosing after the initial stabilization period.

Long-Term Cost Trajectory

Atopica offers a potential cost advantage over time because many dogs can be successfully maintained on reduced dosing schedules. After 2 to 3 months of daily therapy, a veterinary dermatologist may recommend transitioning to every other day or even twice weekly administration. This dose reduction is less commonly achievable with Apoquel, which tends to require consistent daily dosing to maintain itch control. Over the course of a year, a dog that transitions to every-other-day Atopica could see medication costs drop by roughly 50 percent compared to daily Apoquel therapy.

Additional Costs to Consider

Both medications require periodic bloodwork monitoring, typically every 6 to 12 months, which adds $100 to $200 per visit depending on the panel ordered. Dogs on Apoquel may need more frequent skin checks if new lumps or skin infections develop. Dogs starting Atopica sometimes require an initial anti-nausea medication like maropitant (Cerenia) to manage startup gastrointestinal side effects, adding a short-term cost. Factor in the cost of any concurrent topical treatments, medicated shampoos, or supplements that your veterinarian recommends as part of a comprehensive management plan.

Which Conditions Respond Best to Each Medication

While both Apoquel and Atopica are used for allergic skin disease, their different mechanisms make them better suited to different clinical presentations. Veterinary dermatologists often have strong preferences based on the specific diagnosis, the severity of symptoms, and the dog's overall health profile.

When Apoquel May Be the Better Choice

Apoquel excels in situations requiring rapid itch relief, making it ideal for acute allergic flares, seasonal allergies with defined onset and offset periods, and dogs whose primary symptom is intense pruritus without significant secondary infection. It is also a good choice for dogs that cannot tolerate oral medications well, since it is generally easier on the stomach than cyclosporine. Apoquel is frequently the first-line choice for dogs with mild to moderate atopic dermatitis where itch control is the primary treatment goal and where the dog is otherwise healthy with no history of recurrent infections or neoplasia.

When Atopica May Be the Better Choice

Atopica tends to be preferred for more complex immune-mediated skin conditions, perianal fistulas, sebaceous adenitis, and severe chronic atopic dermatitis where long-term immunomodulation is needed. It is also sometimes chosen for dogs with a history of skin infections or tumors, since cyclosporine's immunomodulatory profile differs from Apoquel's JAK inhibition in ways that some dermatologists consider less concerning for these populations. Dogs that need long-term management and whose owners prefer the potential for dose reduction over time may also benefit from Atopica.

Conditions Where Neither Drug Is First-Line

It is important to recognize that neither Apoquel nor Atopica addresses the underlying cause of allergic skin disease. They manage symptoms while the immune system continues to react to allergens. For dogs with identified environmental allergies, allergen-specific immunotherapy (allergy shots or sublingual drops) remains the only treatment that can potentially modify the disease course. Food allergies are managed through strict dietary elimination, not through Apoquel or Atopica. Both drugs are symptomatic treatments, and their use should be part of a broader management plan that includes allergen avoidance, skin barrier support, and treatment of any secondary infections.

Combination Therapy and Topical Support

Many veterinary dermatologists advocate for a multimodal approach to managing allergic skin disease rather than relying on a single oral medication. Combining systemic therapy with topical treatments can improve outcomes, reduce the required dose of oral medication, and provide additional benefits like infection control and skin barrier repair.

Topical Antimicrobial Support

Dogs with allergic skin disease are prone to secondary bacterial and yeast infections because the compromised skin barrier allows opportunistic organisms to proliferate. Topical antimicrobial products containing chlorhexidine or antifungal agents can help manage these secondary infections without adding systemic medication. Regular use of antimicrobial sprays between baths can keep microbial populations in check and reduce the inflammatory load that drives continued itching. This approach is particularly valuable for dogs on immunomodulatory therapy, where the immune system's ability to fight skin infections may be somewhat diminished.

Combining Oral and Topical Treatments

Research has shown that dogs receiving both oral allergy medication and consistent topical therapy often achieve better outcomes than those on oral medication alone. Medicated shampoos with chlorhexidine and miconazole can address both bacterial and fungal components of skin infections. Between baths, topical sprays provide ongoing antimicrobial coverage and help maintain skin hydration. Some veterinarians have found that dogs receiving comprehensive topical support may require lower maintenance doses of Apoquel or Atopica, potentially reducing both side effects and costs over time.

The Role of Skin Barrier Repair

Atopic dogs have inherently compromised skin barriers, often with reduced ceramide levels and altered lipid composition. Topical products designed to support skin barrier function, including ceramide-containing moisturizers and essential fatty acid supplements, can complement oral therapy by addressing this fundamental deficiency. A stronger skin barrier reduces allergen penetration, decreases moisture loss, and makes the skin less hospitable to infectious organisms. This foundational approach supports the effectiveness of whatever oral medication is chosen and may help reduce the frequency of allergic flares.

Monitoring Requirements and Veterinary Follow-Up

Both Apoquel and Atopica require ongoing veterinary monitoring to ensure safety and optimize treatment. The specific monitoring protocols differ based on the medication used, the duration of therapy, and the individual dog's health status.

Baseline and Routine Testing

Before starting either medication, your veterinarian should perform a complete physical examination and baseline bloodwork including a complete blood count (CBC) and serum biochemistry panel. This establishes normal reference values for your dog against which future test results can be compared. For dogs on Apoquel, follow-up bloodwork is recommended every 6 to 12 months, with particular attention to white blood cell counts, liver enzymes, and any changes that might suggest immune compromise. For dogs on Atopica, similar monitoring intervals apply, with additional attention to kidney values since cyclosporine can occasionally affect renal function at higher doses.

Skin Health Monitoring

Beyond bloodwork, regular skin assessments are essential for dogs on either medication. Your veterinarian should evaluate the skin at each visit for signs of secondary infection, new masses or lumps, evidence of demodicosis, and overall response to therapy. For dogs on Apoquel, any new skin lumps should be investigated promptly with fine-needle aspirate, given the theoretical concern about immune surveillance suppression. Dogs on Atopica should be monitored for gingival hyperplasia and papillomatous lesions, which are recognized side effects that typically resolve with dose adjustment.

When to Contact Your Veterinarian Between Visits

Dog owners should be educated about warning signs that warrant immediate veterinary attention during treatment with either medication. These include sudden development of skin infections or abscesses, persistent vomiting or diarrhea (especially with Atopica), any new lumps or rapidly growing masses, signs of urinary tract infection such as frequent urination or straining, lethargy or behavioral changes, and any unexplained weight changes. Early intervention when problems arise is key to safe long-term management with either immunomodulatory drug.

Making the Decision with Your Veterinarian

The choice between Apoquel and Atopica is not one that dog owners should make in isolation. It requires a thorough evaluation of your dog's specific condition, health history, and lifestyle factors, combined with your veterinarian's clinical expertise and familiarity with both medications.

Questions to Ask Your Veterinarian

Prepare for your appointment by asking specific questions: What is the precise diagnosis driving the need for medication? How severe is the disease, and does it require immediate relief or can we wait for a slower-acting treatment to take effect? What are the specific risks for my dog based on age, breed, and concurrent health conditions? Is there a possibility of using one medication short-term while transitioning to another for long-term management? Can we incorporate topical treatments or immunotherapy to reduce the medication burden over time? What monitoring schedule do you recommend, and what will that cost annually?

The Role of Veterinary Dermatologists

For dogs with complex or refractory allergic skin disease, referral to a board-certified veterinary dermatologist can be invaluable. Dermatology specialists have extensive experience with both medications and can offer nuanced recommendations based on the latest research. They may also have access to clinical trials for newer therapies and can perform advanced diagnostic testing to refine the diagnosis. If your dog's allergic skin disease has not responded adequately to initial treatment, or if you are concerned about long-term side effects, seeking a specialist opinion is a worthwhile investment.

Reassessing Treatment Over Time

Whichever medication you and your veterinarian choose initially, the treatment plan should be viewed as dynamic rather than static. Dogs' conditions change over time, new treatment options become available, and long-term data continues to evolve. Regular reassessment of the treatment plan, ideally at least annually, ensures that your dog is receiving the most appropriate and safest therapy. Some dogs may benefit from switching medications, adding topical support, or incorporating immunotherapy as part of an evolving management strategy that adapts to their changing needs.

Apoquel vs Atopica for Dogs FAQ

Q: Can my dog take Apoquel and Atopica together?

Concurrent use of Apoquel and Atopica is generally not recommended because both drugs have immunomodulatory effects, and combining them increases the risk of immune suppression and secondary infections. However, some veterinary dermatologists use short-term overlap when transitioning between medications. For example, a dog switching from Apoquel to Atopica might continue Apoquel during the first few weeks while cyclosporine reaches therapeutic levels. This should only be done under direct veterinary supervision with appropriate monitoring.

Q: Which medication works faster for allergic itch in dogs?

Apoquel works significantly faster than Atopica for itch relief. Most dogs experience noticeable relief within 4 to 24 hours of their first Apoquel dose. Atopica, by contrast, typically requires 2 to 4 weeks before meaningful improvement is observed, with full efficacy often not reached until 4 to 6 weeks of consistent daily dosing. For dogs in acute distress, Apoquel's rapid onset makes it the preferred choice for immediate relief.

Q: Are there generic alternatives to Atopica that are just as effective?

Yes, generic cyclosporine formulations are available and are considered bioequivalent to brand-name Atopica. These generics contain the same active ingredient at the same dose and undergo FDA review to confirm equivalent absorption and efficacy. Generic cyclosporine can cost 30 to 60 percent less than brand-name Atopica, making long-term treatment more affordable. Discuss with your veterinarian whether a generic option is appropriate for your dog.

Q: What are the long-term risks of keeping my dog on Apoquel indefinitely?

Long-term Apoquel use has been associated with increased susceptibility to infections, including skin infections and urinary tract infections, due to its effects on immune signaling pathways. Post-market surveillance has also documented cases of new skin masses and demodicosis in dogs on extended Apoquel therapy. While many dogs tolerate Apoquel well for years, regular veterinary monitoring including bloodwork and skin assessments is essential. The FDA label notes that Apoquel may increase susceptibility to infection and exacerbate neoplastic conditions.

Q: Is Atopica safe for puppies?

Atopica is not recommended for dogs under 6 months of age or those weighing less than 4 pounds. The safety of cyclosporine in very young puppies has not been extensively studied, and the developing immune system may be more vulnerable to immunomodulatory effects. Similarly, Apoquel is not approved for dogs under 12 months. For puppies with allergic skin disease, veterinarians typically rely on topical treatments, antihistamines, and environmental management until the dog is old enough for systemic immunomodulatory therapy.

Q: Can I use topical treatments instead of Apoquel or Atopica?

Topical treatments alone may be sufficient for mild, localized allergic skin disease. Medicated shampoos, antimicrobial sprays, and topical anti-itch preparations can provide relief for some dogs without the need for systemic medication. However, for moderate to severe atopic dermatitis affecting large areas of the body, topical therapy alone is usually insufficient to control symptoms. Most veterinary dermatologists recommend topical treatments as complementary to systemic therapy rather than as a replacement, using them to reduce the medication dose needed and to manage secondary infections.

Sources

Olivry, T., et al. (2015). Treatment of canine atopic dermatitis: updated guidelines from the International Committee on Allergic Diseases of Animals. Veterinary Dermatology, 26(4), 210-e49.

Cosgrove, S.B., et al. (2015). Efficacy and safety of oclacitinib for the control of pruritus and associated skin lesions in dogs with canine allergic dermatitis. Veterinary Dermatology, 26(3), 127-e33.

Steffan, J., et al. (2006). Cyclosporin A pharmacokinetics and efficacy in the treatment of atopic dermatitis in dogs. Journal of Veterinary Pharmacology and Therapeutics, 29(1), 1-10.

Little, P.R., et al. (2015). A blinded, randomized clinical trial comparing the efficacy and safety of oclacitinib and ciclosporin for the control of atopic dermatitis in client-owned dogs. Veterinary Dermatology, 26(1), 23-e8.

Nuttall, T., et al. (2019). Update on pathogenesis, diagnosis, and treatment of atopic dermatitis in dogs. Journal of the American Veterinary Medical Association, 254(11), 1291-1300.

Related Reading

• Apoquel vs Cytopoint for Dogs, comparing another popular allergy treatment option
• Cyclosporine (Atopica) for Dogs, deep dive into cyclosporine therapy
• Prednisone for Dogs' Skin, understanding corticosteroid alternatives
• Topical vs Oral Medications for Dog Skin, comparing delivery methods for skin treatments
• Natural Remedies for Dog Skin Issues, evidence-based look at complementary approaches

Emiel Maddens

Founder of Vetified. Develops topical antifungal and antimicrobial formulations for companion animals. Vetified products are listed on DailyMed and manufactured through FDA-registered facilities in the United States.